Illimis Therapeutics Secures $42 Million to Propel CNS and Immune Disease Innovations Illimis Therapeutics has successfully closed a Series B funding round, raising $42 million to accelerate the development of its CNS and immune disease drug pipeline, underscoring strong investor confidence.

Illimis Therapeutics Secures $42 Million to Propel CNS and Immune Disease Innovations #South_Korea #Seoul #CNS_Drug_Development #Illimis_Therapeutics #GAIA_platform